NCT02626312 2026-04-16
Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
Clinical Trials
157 trialsNCT03778957 2026-04-15
EMERALD-1
AstraZeneca
Phase 3 Active not recruiting
NCT04785534 2026-04-15
Surveys, Blood Testing, and Fibroscan in Screening for Liver Fibrosis and Liver Cirrhosis
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT03520660 2026-04-14
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
National Institutes of Health Clinical Center (CC)
Phase 4 Active not recruiting
NCT04145141 2026-04-14
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
National Institutes of Health Clinical Center (CC)
Active not recruiting
NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02772003 2026-04-13
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02867592 2026-04-13
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02968810 2026-04-13
Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05666271 2026-04-13
Radiofrequency Ablation for Hepatocellular Carcinoma Using Octopus MP Electrodes
Seoul National University Hospital
Active not recruiting
NCT06679985 2026-04-13
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Active not recruiting
NCT07444905 2026-04-13
Prospective Evaluation of a Locked Risk-Stratified Surveillance Strategy for Extrahepatic Metastasis in Hepatocellular Carcinoma
Tongji Hospital
Active not recruiting
NCT04180072 2026-04-09
Atezolizumab Plus Bevacizumab With HCC and HBV Infection
National Health Research Institutes, Taiwan
Phase NA Active not recruiting
NCT05858736 2026-04-09
PRESERVE-009
OncoC4, Inc.
Phase 1 Active not recruiting
NCT05301842 2026-04-07
EMERALD-3
AstraZeneca
Phase 3 Active not recruiting
NCT03916627 2026-04-06
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
Regeneron Pharmaceuticals
Phase 2 Active not recruiting
NCT04039607 2026-04-06
CheckMate 9DW
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT03186898 2026-04-03
Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer
NRG Oncology
Phase 3 Active not recruiting
NCT03680508 2026-04-02
TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer
University of Hawaii
Phase 2 Active not recruiting
NCT05063565 2026-03-27
ROWAN
Boston Scientific Corporation
Phase 2 Active not recruiting
NCT05622136 2026-03-27
STRAT-aHCC
Instituto do Cancer do Estado de São Paulo
Phase 2 Active not recruiting
NCT07493070 2026-03-25
Ultra-stable Iodized Oil-Chemo Embolization Seq Thermal Ablation in Early Liver Ca
Fujian Medical University Union Hospital
Phase NA Active not recruiting
NCT03937830 2026-03-24
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT04008797 2026-03-24
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Eisai Inc.
Phase 1/2 Active not recruiting
NCT04514484 2026-03-23
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03298451 2026-03-20
HIMALAYA
AstraZeneca
Phase 3 Active not recruiting
NCT04102098 2026-03-19
IMbrave050
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05128032 2026-03-19
PEDIR
Massachusetts General Hospital
Phase NA Active not recruiting
NCT06040099 2026-03-19
EMERALD-Y90
AstraZeneca
Phase 2 Active not recruiting
NCT03028311 2026-03-10
Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT06859840 2026-03-10
LEAF
Zhejiang University
Phase NA Active not recruiting
NCT06084884 2026-03-09
ATHENA
AstraZeneca
Phase 1/2 Active not recruiting
NCT03264664 2026-03-06
Study of E7386 in Participants With Selected Advanced Neoplasms
Eisai Inc.
Phase 1 Active not recruiting
NCT03847428 2026-03-06
EMERALD-2
AstraZeneca
Phase 3 Active not recruiting
NCT05103631 2026-03-06
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
Baylor College of Medicine
Phase 1 Active not recruiting
NCT06018857 2026-03-06
Registry 17-009: Multi-Institutional Study Examining Patients With HCC Undergoing Liver Transplantation
The Cleveland Clinic
Active not recruiting
NCT04563338 2026-03-05
An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)
University Health Network, Toronto
Phase 2 Active not recruiting
NCT04721132 2026-03-05
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05953337 2026-03-04
Radioembolization Trial Utilizing Eye90 Microspheresâ„¢ for the Treatment of Hepatocellular Carcinoma (HCC)
ABK Biomedical
Phase NA Active not recruiting
NCT03833700 2026-02-27
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
Eisai Inc.
Phase 1 Active not recruiting
NCT07437859 2026-02-27
Exploring the Application of 3D Bioprinting for Personalized Treatment in Primary Liver Cancer With Tumor Microenvironment
Peking Union Medical College Hospital
Active not recruiting
NCT02519348 2026-02-17
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
MedImmune LLC
Phase 2 Active not recruiting
NCT03519997 2026-02-11
A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma
University of Texas Southwestern Medical Center
Phase 2 Active not recruiting
NCT05267080 2026-02-06
RESPECT
Cardiovascular and Interventional Radiological Society of Europe
Active not recruiting
NCT02967848 2026-02-05
LiverINSPECT
Royal North Shore Hospital
Active not recruiting
NCT04459273 2026-02-05
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT07380633 2026-02-02
Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial
Sun Yat-sen University
Phase 2 Active not recruiting
NCT04712643 2026-01-30
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT01918683 2026-01-29
TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients
Abramson Cancer Center at Penn Medicine
Phase NA Active not recruiting
NCT05113186 2026-01-29
LENVABLA
Assistance Publique - Hôpitaux de Paris
Phase 2 Active not recruiting